Literature DB >> 20349094

Effects of GDF5 overexpression on embryonic rat dopaminergic neurones in vitro and in vivo.

David B O'Sullivan1, Patrick T Harrison, Aideen M Sullivan.   

Abstract

Transplantation of embryonic dopaminergic neurones has shown promise for the treatment of Parkinson's disease (PD), but this approach is limited by the poor survival of the transplanted cells. Exogenous dopaminergic neurotrophic factors such as growth/differentiation factor 5 (GDF5) have been found to enhance the survival of transplanted dopaminergic neurones. However, this approach is limited by the rapid degradation of such factors in vivo; thus, methods for long-term delivery of these factors are under investigation. The present study shows, using optimised lipid-mediated transfection procedures, that overexpression of GDF5 significantly improves the survival of dopaminergic neurones in cultures of embryonic day (E) 13 rat ventral mesencephalon (VM) and protects them against 6-hydroxydopamine (6-OHDA)-induced toxicity. In another experiment, E13 VM cells were transfected with GDF5 after 1 day in vitro (DIV), then transplanted into 6-OHDA-lesioned adult rat striata after 2 DIV. The survival of these E13 VM dopaminergic neurones after transfection and transplantation was as least as high as that of freshly dissected E14 VM dopaminergic neurones, demonstrating that transfection was not detrimental to these cells. Furthermore, GDF5-overexpressing E13 VM transplants significantly reduced amphetamine-induced rotational asymmetry in the lesioned rats. This study shows that lipid-mediated transfection in vitro prior to transplantation is a valid approach for the introduction of neurotrophic proteins such as GDF5, as well as lending further support to the potential use of GDF5 in neuroprotective therapy for PD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20349094     DOI: 10.1007/s00702-010-0392-9

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  60 in total

Review 1.  Sustained delivery of GDNF: towards a treatment for Parkinson's disease.

Authors:  A D Zurn; H R Widmer; P Aebischer
Journal:  Brain Res Brain Res Rev       Date:  2001-10

2.  Engrailed genes are cell-autonomously required to prevent apoptosis in mesencephalic dopaminergic neurons.

Authors:  Lavinia Albéri; Paola Sgadò; Horst H Simon
Journal:  Development       Date:  2004-06-02       Impact factor: 6.868

Review 3.  A review of recent advances in stereology for quantifying neural structure.

Authors:  T M Mayhew
Journal:  J Neurocytol       Date:  1992-05

Review 4.  Progress in Parkinson's disease-where do we stand?

Authors:  André Toulouse; Aideen M Sullivan
Journal:  Prog Neurobiol       Date:  2008-06-05       Impact factor: 11.685

Review 5.  Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease.

Authors:  P Hagell; P Brundin
Journal:  J Neuropathol Exp Neurol       Date:  2001-08       Impact factor: 3.685

Review 6.  Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model.

Authors:  A Björklund; D Kirik; C Rosenblad; B Georgievska; C Lundberg; R J Mandel
Journal:  Brain Res       Date:  2000-12-15       Impact factor: 3.252

Review 7.  In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease.

Authors:  Jeffrey H Kordower
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

8.  Cloning and expression of recombinant human growth/differentiation factor 5.

Authors:  G Hötten; H Neidhardt; B Jacobowsky; J Pohl
Journal:  Biochem Biophys Res Commun       Date:  1994-10-28       Impact factor: 3.575

9.  Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons.

Authors:  K Krieglstein; C Suter-Crazzolara; G Hötten; J Pohl; K Unsicker
Journal:  J Neurosci Res       Date:  1995-12       Impact factor: 4.164

10.  A rat embryo staging scale for the generation of donor tissue for neural transplantation.

Authors:  E M Torres; U M Weyrauch; R Sutcliffe; S B Dunnett
Journal:  Cell Transplant       Date:  2008       Impact factor: 4.064

View more
  6 in total

1.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

Review 2.  Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-02-07       Impact factor: 5.590

Review 3.  TGF-β Family Signaling in Neural and Neuronal Differentiation, Development, and Function.

Authors:  Emily A Meyers; John A Kessler
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-08-01       Impact factor: 10.005

4.  Transplantation of novel human GDF5-expressing CHO cells is neuroprotective in models of Parkinson's disease.

Authors:  Daniel J Costello; Gerard W O'Keeffe; Fiona M Hurley; Aideen M Sullivan
Journal:  J Cell Mol Med       Date:  2012-10       Impact factor: 5.310

Review 5.  Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.

Authors:  Shane V Hegarty; Gerard W O'Keeffe; Aideen M Sullivan
Journal:  Neural Regen Res       Date:  2014-10-01       Impact factor: 5.135

Review 6.  Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.

Authors:  Gerard W O'Keeffe; Shane V Hegarty; Aideen M Sullivan
Journal:  Neuronal Signal       Date:  2017-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.